The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply ...

Researchers believe discovery will springboard research to make more tolerable, effective weight loss treatments accessible ...

The single ascending dose trial enrolled lean or overweight men with an average BMI of 26.6. Study participants were then ...

Danish biotech Gubra A/S said its experimental obesity drug showed weight loss and mild side effects in a small study, ...

With promising Phase 1 results in hand, Metsera hopes to develop a longer-lasting GLP-1 injection along with other types of ...

Just sev­en months af­ter un­veil­ing with $290 mil­lion, obe­si­ty biotech Met­sera is back with an­oth­er $215 mil­lion.

[7] Exenatide extended release: A long-acting RA version of exenatide administered as an injection weekly, usually under the ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

While semaglutide works by hampering appetite and controlling blood sugar levels by mimicking the GLP-1 hormone, cagrilintide ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...